MAIA Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
MAIA Biotechnology, Inc. (MAIA), a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on September 29, 2025. The filing discloses the entry into a Material Definitive Agreement regarding a private placement of equity securities and amendments to existing warrants.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction with the following financial terms:
- Total Gross Proceeds: Approximately $2,253,896 (prior to offering expenses).
- Investor Shares Sold: 1,714,536 shares of Common Stock at $1.30 per share.
- Director Shares Sold: 19,230 shares of Common Stock at $1.30 per share.
- Warrants Issued: Warrants to purchase 1,733,766 shares total (1,714,536 Investor Warrants and 19,230 Director Warrants).
- Warrant Exercise Price: $1.57 per share (representing the "Minimum Price" under NYSE American Rule 713).
- Warrant Terms: Exercisable commencing six months after issuance with a three-year term.
- Major Subscriber: FGMK Business Holdings, LLC (a greater than 5% holder) subscribed for approximately $1 million in shares and warrants.
Material Changes and Warrant Amendments
In addition to the new issuance, the Company amended existing common stock purchase warrants originally issued on February 24, 2025:
- Shares Affected: 1,396,667 shares of common stock underlying existing warrants.
- Price Reduction: The exercise price was reduced from $1.87 per share to $1.30 per share.
- Major Holder Impact: FGMK Holdings LLC amended warrants covering 1,350,000 shares.
Use of Proceeds, Outlook, and Risks
Use of Proceeds: The Company intends to use net proceeds to fund the starting costs for Step 1 of Part C of the Phase II trial for THIO-101 and for general working capital.
Closing Date: The private placement is expected to close on October 1, 2025, subject to customary closing conditions.
Risks and Contingencies: The securities are being issued as restricted securities under Rule 144 and do not contain registration rights. The offering relies on exemptions from registration under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933.
Key Facts for Investor Verification
- Verify the closing of the transaction on or about October 1, 2025, and the actual net proceeds received after deducting offering expenses.
- Confirm the dilution impact of the 1,733,766 new warrants and the 1,733,766 shares issued in the private placement.
- Monitor the progress and funding requirements for the THIO-101 Phase II trial (Step 1 of Part C) to ensure proceeds are sufficient.
- Review the full text of the Securities Purchase Agreement and Warrant Amendments (Exhibits 10.1, 10.2, 4.1, 4.2) for specific adjustment provisions and covenants.